Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.53 |
| ▸ | JAK1 | P23458 | 14/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375100 | 0.91 | JAK2 (0.57) | JAK2JAK1HDAC6 | |
| SCHEMBL3376937 | 0.86 | JAK2 (0.50) | JAK2JAK1 | |
| SCHEMBL3374890 | 0.85 | JAK2 (0.49) | JAK2JAK1HDAC6 | |
| SCHEMBL3374827 | 0.83 | JAK2 (0.47) | JAK2JAK1HDAC6 | |
| SCHEMBL3373926 | 0.82 | JAK2 (0.44) | JAK2JAK1HDAC6CHRNB2CHRNB4 | |
| SCHEMBL3374032 | 0.82 | JAK2 (0.53) | JAK2JAK1HDAC6 | |
| SCHEMBL3373671 | 0.81 | JAK2 (0.45) | JAK2JAK1HDAC6 | |
| SCHEMBL14563475 | 0.81 | JAK2 (0.67) | JAK2JAK1 | |
| SCHEMBL3434304 | 0.80 | JAK2 (0.49) | JAK2JAK1HDAC6 | |
| SCHEMBL4125309 | 0.80 | JAK1 (0.49) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885HDAC6 1687/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885HDAC6 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.